(C) Horizon Discovery 2012 - Eric T. RhodesMitigating risks and developing the U.S. business

January 2012. Eric T. Rhodes, CTO of Horizon Discovery has to mitigate major risks for the company’s business, in particular in the US which is the most mature market for the company’s products. B2Bioworld took a closer look at the strategy.


If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 2 pages
- Includes comparison of homologous recombination efficiency (AAV vs. Plasmids)

Full Company License enquire here

Back to section

Related Editorial Articles

TALEs, Zinc Fingers, or Meganucleases
A Practice View from Crop Research and Breeding.
Johan Bottermman, Head of Product Research - Bayer CropScience NV

Drug Testing with Embryonic Stem Cells
- Towards standards for assays

Stem Cells – Failings and Deliveries
Hugh Ilyine, longtime COO of Stem Cell Sciences looks at clinical trials, reimbursement prospects, and interest of venture capital

Eli Lilly: Is that worth a dollar, or a million dollars?

Stem Cell Research Now and in the Future
Patrick Vallance, today President Pharmaceuticals, R&D of GlaxoSmithKline on company strategy and the the role of cancer stem cells

Novo Nordisk: Doing our business a little bit differently than the others in industry
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk on stem cell approaches to diabetes

Leroy Hood: Thinking Further about Stem Cells